Brevan Howard Capital Management’s 10x Genomics TXG Stock Holding History

Brevan Howard Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$548K	Buy	+25,812	New	+$516K	﹤0.01%	1247
2025 Q4	–	Sell	-103,951	Closed	-$1.22M	–	2288
2025 Q3	$1.22M	Buy	103,951 +52,972	+104%	+$691K	0.01%	809
2025 Q2	$590K	Buy	50,979 +36,661	+256%	+$334K	﹤0.01%	1279
2025 Q1	$125K	Sell	14,318 -363	-2%	-$4.58K	﹤0.01%	1035
2024 Q4	$211K	Sell	14,681 -10,929	-43%	-$172K	﹤0.01%	895
2024 Q3	$578K	Buy	+25,610	New	+$529K	﹤0.01%	646
2024 Q2	–	Sell	-11,012	Closed	-$413K	–	1405
2024 Q1	$413K	Sell	11,012 -6,639	-38%	-$292K	﹤0.01%	521
2023 Q4	$988K	Buy	+17,651	New	+$768K	0.01%	237

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's TXG Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in 10x Genomics (TXG) in Q1 2026: 25,812 shares worth $548K. The stake represents ﹤0.01% of the portfolio and ranks #1247 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in TXG as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in TXG in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.22M in Q3 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Brevan Howard Capital Management held 25,812 shares of 10x Genomics worth $548K as of Q1 2026.
10x Genomics was a new Brevan Howard Capital Management position in Q1 2026.
10x Genomics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1247 holding.
Brevan Howard Capital Management first reported a position in 10x Genomics in Q4 2023 and has held it in 8 quarters since.
Brevan Howard Capital Management's 10x Genomics position peaked at $1.22M in Q3 2025.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.